MedPath

Validation of a Boindicator as Monitoring Tool for Oyster Norovirus Outbreak

Not Applicable
Withdrawn
Conditions
Gastroenteritis Norovirus
Interventions
Other: Oyster consumption
Registration Number
NCT06568380
Lead Sponsor
Central Hospital, Nancy, France
Brief Summary

Noroviruses are responsible for 700M of annual cases of gastroenteritis, of which 15M are directly related to the consumption of contaminated food, including oysters. Current regulations do not require control of human noroviruses in shellfish. However, an ISO standard recommended to detect their genome in high-risk foodstuffs. However, presence of viral genome doesn't testify to the presence of infectious particles. Routine application of this standard would therefore wrongly lead to the withdrawal of shellfish from market, since norovirus genomes are widely found in the environment and in food without indicating a viral risk. Given the difficulty of cultivating human noroviruses in vitro and thus of discriminating infectious particles from non-infectious particles only based on genome detection, it is necessary to identify an indicator of the infectious nature of these pathogenic viruses. To be suitable, the indicator must first be associated with the presence of norovirus genome in the environment. This is the case of fecal bacteriophage F-specific RNA. Since bacteriophages are cultivable in the laboratory, it is easy to estimate the proportion of genomes of these bacteriophages corresponding to infectious particles. To confirm this indicator, it is necessary to demonstrate a relationship between the presence of infectious bacteriophages with that of infectious norovirus. This is only estimable by the occurrence of a gastroenteritis after consumption of a contaminated food by humans. We propose this randomized controlled clinical trial to evaluate the incidence of norovirus infection after consumption of oysters free from or containing infectious F-specific RNA bacteriophages.

The purpose of this study is to evaluate if norovirus infections incidence is significantly weak after the consumption of oysters free of F-specific infectious RNA bacteriophages, compared to the consumption of oysters containing these same infectious bacteriophages.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Informed consent signed
  • Health status
  • No seafood allergy
  • Nancy city residents
Exclusion Criteria
  • Recent gastroenteritis (<6 months)
  • Fragile health person proximity
  • Oysters consumption during the study
  • Pregnancy or breastfeeding
  • "nonsecretor" phenotype

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Noro+ Phage-Oyster consumptionOysters positives for norovirus genome and negatives for infectious bacteriophages
Noro+ Phage+Oyster consumptionOysters positives for both norovirus genome and infectious bacteriophages
Noro- Phage-Oyster consumptionOysters negatives for both norovirus genome and infectious bacteriophages
Noro- Phage+Oyster consumptionOysters negatives for norovirus genome and positives for infectious bacteriophages
Primary Outcome Measures
NameTimeMethod
Immunoglobulin A (IgA) detection in feceswithin 3-5 days after consumption

In case of asymptomatic infection, IgA are secreted

Norovirus concentration in feces (genome copy number/grammes of feces)Baseline (J0) and during symptoms if any or within 36-60 hours after consumption in another case

A norovirus genome augmentation may indicate virus replication

Gastroenteritis symptomswithin 3 days after consumption
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHRU Nancy

🇫🇷

Nancy, Lorraine, France

© Copyright 2025. All Rights Reserved by MedPath